Connect with us

Business

Is CV Sciences Inc (OTCMKTS:CVSI) Back on Track?

Published

on

CV Sciences Inc (OTCMKTS:CVSI) is possibly beginning to show some renewed signs of life following a period of heavy doubt that was initially sparked by a research note from Citron and Andrew Left. The notorious short-seller hammered the company with allegations, and the circling sharks of the class-action legal community did the rest. But shares of the stock never really wilted, and now the specter of a possible short squeeze cannot be dismissed.

To further flesh out the narrative of Wednesday’s action, the company just announced that the Company is now sponsoring Rodale Institute’s research on organic hemp farming alongside industry leaders Patagonia and Dr. Bronner’s. According to the release, the Rodale Institute is the nation’s leading organic farming institution, dedicated to pioneering organic farming through research and outreach.

CV Sciences Inc (OTCMKTS:CVSI) bills itself as a company that operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.

In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($7.2M against $3M).

CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada.

Moreover, CV Sciences, Inc. operates as a life science company. It operates through two segments, Specialty Pharmaceuticals and Consumer Products. The company focuses on developing and commercializing prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction.

The company also engages in the development, manufacture, marketing, and sale of consumer products containing plant-based CBD under the PlusCBD Oil name in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.

 

The Squeeze is On?

We started off by noting that CVSI just hit the wires with the announcement that the Company is now sponsoring Rodale Institute’s research on organic hemp farming alongside industry leaders Patagonia and Dr. Bronner’s.

Joseph Dowling, Chief Executive Officer at CV Sciences, states, “We are thrilled to expand our robust support of hemp farming research throughout the United States to increase organic production of hemp with such a forward-thinking organization like the Rodale Institute.  We believe that hemp can play a large role in the future of agriculture and look forward to working with Rodale to further organic hemp production.”

The stock is up on the news. Overall, shares of CVSI have rallied about 16% over the past week. That sets up an interesting context for the action tomorrow, and lot will come down to how the stock handles its next confrontation with the $6/share level.

“We appreciate the support of CV Sciences as we explore hemp’s role in soil health,” said Jeff Moyer, Executive Director of the Rodale Institute. “We know that healthy soil equals healthy food equals healthy people and a healthy planet. Having a partner like CV Sciences allows us to have a much larger impact.”

CV Sciences Inc (OTCMKTS:CVSI) generated sales of $12.3M, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 53% on the top line.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

FEATURED STORIES

INDUSTRIAL HEMP18 hours ago

Generex Biotechnology Corporation (OTCMKTS:GNBT) Submits Pre-IND For Ii-Key-SARS-CoV-2 Vaccine To The FDA

Post Views: 118 Generex Biotechnology Corporation (OTCMKTS:GNBT) submitted a Pre-IND update to the FDA outlining its proposed Phase I/II clinical...

Business4 days ago

cbdMD Inc. (NYSEAMERICAN:YCBD) Protecting Its CBD Technologies Through Patents and expands Partnership With Bellator MMA

Post Views: 280 cbdMD Inc. (NYSEAMERICAN:YCBD) announced an extension of the exclusive Official CBD marketing partnership with ViacomCBS’s wholly-owned subsidiary...

Business4 days ago

CLS Holdings USA Inc (OTCMKTS:CLSH) Increases Revenues In June 2020 By 5.35%

Post Views: 181 CLS Holdings USA Inc (OTCMKTS:CLSH) posted a growth of 5.35% YoY to $1.102 million in June 2020....

Business5 days ago

Canopy Rivers Inc.’s (OTCMKTS:CNPOF) Portfolio Companies Expanding Their Reach In Canada And The US

Post Views: 234 Canopy Rivers Inc.’s (OTCMKTS:CNPOF) three portfolio companies recently announced plans to expand their product offering for recreational...

Business5 days ago

AgraFlora Organics International Inc. (OTCMKTS:AGFAF) Processes Around 1,000KG Of CBD Crude Oil From 10,000Kg Of Hemp

Post Views: 299 AgraFlora Organics International Inc. (OTCMKTS:AGFAF) Toronto-based Sustainable Growth Strategic Capital Corp subsidiary in partnership with MicroC45 produced...

Business6 days ago

Marimed Inc (OTCMKTS:MRMD) Retires $7.3 Million Short-term Debt: Robust Sales Of Adult-Use Programs Improves Cash Flow

Post Views: 167 Marimed Inc (OTCMKTS:MRMD) restructured its debt to provide financial flexibility at reduced interest rates. Marimed replaced the...